Remegen

China
Yijing, Shanxi, China

Company profile

Remegen company profile

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Business identity

Contact email
[email protected]
Phone number
+86 05353573511
Operating status
Active
Company type
For Profit
Employee range
1,001-5,000 employees
Revenue range
$10M-$100M
Founded
2008-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
2
Total equity funding
$100M
Last funding
Private Equity / $100M / 2020-03-17
Last equity funding
Private Equity / $100M
Investors
18
Lead investors
2
Founders
2
Articles
110
Exited on
2020-11-09

Founders and investors

Founders

Jianmin FangWang Weidong

Lead investors

Lake Bleu CapitalLilly Asia Ventures

Investors

Lilly Asia VenturesLoyal Valley CapitalOrbiMedShenzhen Capital GroupVivo Capital